XT
ADIL

XTX Topco’s Adial Pharmaceuticals ADIL Stock Holding History

XTX Topco’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,084
Closed -$11.5K – 3783
2025
Q4 		$11.5K Buy
+2,084
New +$16.9K ﹤0.01% 3167

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return

XTX Topco's ADIL Position: Q1 2026 in Review

XTX Topco sold out of Adial Pharmaceuticals (ADIL) in Q1 2026, closing a stake of 2,084 shares — an estimated $11.5K sold.

XTX Topco first reported a position in ADIL in Q4 2025 and held it in 1 quarter. The position peaked at $11.5K in Q4 2025. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • XTX Topco reported no remaining Adial Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 2,084 Adial Pharmaceuticals shares in Q1 2026, an estimated $11.5K.
  • XTX Topco first reported a position in Adial Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • XTX Topco's Adial Pharmaceuticals position peaked at $11.5K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.